MedTrace Logo

Ranibizumab Plus Indomethacin

NCT03261635 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-08-25

No results posted yet for this study

Summary

To evaluate whether indomethacin eyedrops plus intravitreal ranibizumab (IVR) provides additional benefit over IVR monotherapy for treatment of choroidal neovascularization (CNV) in age-related macular degeneration.

Conditions

  • Macular Edema

Interventions

DRUG

Ranibizumab Injection

patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata

DRUG

Indomethacin

patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months

Sponsors & Collaborators

  • Università degli Studi di Brescia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-07
Primary Completion
2016-12-07
Completion
2017-07-25

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03261635 on ClinicalTrials.gov